Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: the AEGIS-I trial (ApoA-I Event Reducing in Ischemic Syndromes I)
The flow includes retention warnings and stacked discount offers
Assessment may consider: Symptoms, when they started, whether they are progressing and whether neurological symptoms are present
European journal of clinical nutrition , 72 (1), 105-111
Business Type Supplier Employee Count 60 Establishment 2017 Working Days To Related Products Explore Related Categories More Products From This Seller Seller Details Shanghai, Shanghai Name Hana Chen Address Room 202, Building 7, No
Curr Opin Investig Drugs